Business Wire

MA-CYTOTRONICS

Share
CytoTronics Breaks Scalability Barriers for Monitoring Live Cell Function, Reveals Pixel Octo for High-Throughput Cell Biology Discovery Applications

CytoTronics, Inc., a pioneer of semiconductor-based platforms for discovery in cell biology, introduced its high-throughput Pixel™ Octo system at the International Society for Stem Cell Research (ISSCR 2024) in Hamburg, Germany.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240709748131/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

CytoTronics is launching its high-throughput Pixel™ Octo system (right) at the International Society for Stem Cell Research (ISSCR 2024) in Hamburg, Germany. The ISSCR conference also marks the European reveal of CytoTronics’ product portfolio, including the entry-level Pixel Primo (left), a single plate reader that brings accessibility to researchers. (Photo: Business Wire)

This new addition to the Pixel lineup integrates the company’s semiconductor-to-live-cell interface in an environmental controlled benchtop system to deliver live cell measurements for up to eight 96-well Pixel plates simultaneously. When paired with laboratory robotic automation, the Pixel Octo offers full scalability in high-throughput cell biology applications. The ISSCR conference also marks the European reveal of CytoTronics’ product portfolio, including the entry-level Pixel Primo, a single plate reader that brings accessibility to researchers for under US$30,000.

Pixel assesses live cell function at single-cell resolution, allowing scientists to simultaneously monitor cell viability, morphology, electrophysiology, and more while generating electrical ‘images’ with single-cell spatial resolution. It dramatically accelerates the scale at which cell biology applications can be executed, and the breadth and depth of live-cell insights obtained. Pixel enables new applications for endothelial and epithelial cells, cancer cell biology, mechanism of action/toxicology, stem cell biology, cardiac function, and neural function.

Scale up of in vitro cell-based assays is challenging. Traditionally, these screening assays at high scale use hundreds of 96- or 384- well plates to measure simple cellular properties (e.g., "live or dead" screens) to select the most prospective 'hits' of interest, which are then 'scaled down' to verify key effects on cellular functions. Pixel gives researchers a highly sophisticated tool to start key investigations first, get the functional phenotypic assets they cannot get through imaging and other basic techniques, and easily scale these newly developed assays to high-throughput workflows.

The Pixel plate, a proprietary 96-well electronic microplate embedded with custom-designed semiconductor microchips at the base of each well, is at the core of CytoTronics’ Pixel platform. Cells grow in culture media on top of a microarray containing over 100,000 nanoscale electrode-based sensors, enabling thousands of measurements to be taken per well on a single-cell level, on any cell type, spheroid, or 3D organoid system.

In-vitro cell-based assays can initially be developed on Pixel Primo, a single plate reader that can be placed in any standard cell culture incubator. Cell biologists can then scale those assays 8× on Pixel Octo, a self-contained benchtop system complete with a dedicated incubator to regulate temperature, CO2, humidity, and oxygen. Labs can integrate Pixel Octo with industry standard robotic and liquid handling platforms, and multiple systems can be run in parallel for high-throughput applications. Availability of 384-well Pixel plates later in 2024 raises the scalability bar significantly, adding capability to screen tens of thousands of wells simultaneously.

“There’s a tremendous unmet need in cell biology discovery applications to measure the unique cell parameters that Pixel captures. It unlocks new applications and reveals data that scientists haven’t been able to study before,” said Jeffrey Abbott, Ph.D., Co-Founder and CEO of CytoTronics. “Pixel Octo takes the power of our unique semiconductor-to-biology interface from assay development in a single plate and unleashes it for high-throughput applications, from exploratory assays on a single Pixel plate to fully validated cell-based applications running at industrial scale.”

“Our early access program for the Pixel Primo kicked off in February and already has 20 global partners spanning biotech, pharmaceutical, academic, cell and organoid providers, and computational biology organizations who are very quickly gaining traction on their applications,” said Duane Sword, Co-Founder and CBO at CytoTronics. “Pixel Octo was designed with scalability in mind and provides cell monitoring and data collection at unprecedented scale. Importantly, Pixel is complementary with imaging and HCS (high content screening) techniques and designed to integrate with standard automation workflows. Pixel is rich with information on biology never seen before, let alone at scale. Hence, we have designed the system with a cloud-centric architecture spanning measurement design, execution, analysis and reporting.”

Through the CytoTronics early access program, customers receive a Pixel Primo, 96-well Pixel plates and Pixel Pro, a cloud-based control and interactive analysis software. A starting list price of under $30K (USD) makes it easy for labs to evaluate Pixel as the next frontier of their cell biology research programs.

To learn more about Pixel or enroll in the early access program, visit www.cytotronics.com. You can also visit CytoTronics at ISSCR in Hall H booth #1016 and attend our talks on “Electrical imaging: live cell characterization from stem cell biology to phenotypic disease models”, presented by Shalaka Chitale, CytoTronics’ Director of Biology, Thursday July 11 at 9:10am - 9:20am and Friday July 12 at 6:00pm – 6:30pm.

About Pixel

CytoTronics’ breakthrough semiconductor-to-live-cell interface powered by microchips enables thousands of multi-modal readouts on any cell type or organoid system. Live cell function is monitored on a Pixel plate, a proprietary 96- or 384-well microplate embedded with microchips at the base of each well. Cells grow in culture media on top of a microarray containing over 100,000 nanoscale electrode-based sensors, allowing thousands of measurements to be taken per well. Pixel Primo and Octo offer simultaneous monitoring of cells across all wells of either a single Pixel plate or eight at the same time. Cloud-based Pixel Pro software enables applications across multiple cell types and organoids with cloud-based control and interactive analysis of the data-rich, live cell measurements collected.

About CytoTronics

At CytoTronics, we are transforming cell biology discovery with our high-throughput, semiconductor-based platforms. Our Pixel systems provide live cell insights with single-cell resolution across all cell types. By seamlessly integrating semiconductors with conventional microplates, Pixel unlocks multi-modal electrical, electrochemical, and electrophysiological capabilities, delivering an unprecedented scope of data collection and scale-up for cell biology research, drug development, and pharmaceutical manufacturing applications. Established as a spin-off from Harvard University in 2021, we are headquartered in Boston, Massachusetts. Learn more at www.cytotronics.com or follow us on LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240709748131/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release

Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release

Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release

MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye